BACKGROUND: the STOPP criteria advise against the use of long-acting benzodiazepines (LBs). OBJECTIVE: to study whether LBs are associated with a higher fall risk than short-acting benzodiazepines (SBs) (elimination half-life ≤ 10 h). METHODS: we used base-line data and prospective fall follow-up from the Longitudinal Aging Study Amsterdam, a longitudinal cohort study including 1,509 community-dwelling older persons (Study 1) and from a separate fall prevention study with 564 older persons after a fall (Study 2). Time to the first fall after inclusion and number of falls in the first year after inclusion were the primary endpoints. RESULTS: both in Study 1 and Study 2 the use of SBs was associated with time to the first fall, hazard ratio (HR) 1.62 (95% CI: 1.03-2.56) and HR 1.64 (95% CI: 1.19-2.26),respectively. LBs were not significantly associated with time to first fall, HR 1.40 (0.85-2.31) and HR 1.08 (0.72-1.62). In both studies, the use of SBs was also associated with number of falls, odds ratio (OR) 1.28 (95% CI: 1.01-1.61) and OR 1.37 (95% CI: 1.10-1.70). LBs were not significantly associated with number of falls, OR 1.23 (0.96-1.57) and 1.10 (0.82-1.48). CONCLUSIONS: the use of SBs is not associated with a lower fall risk compared with LBs. The use of both SBs and LBs by old persons should be strongly discouraged.
BACKGROUND: the STOPP criteria advise against the use of long-acting benzodiazepines (LBs). OBJECTIVE: to study whether LBs are associated with a higher fall risk than short-acting benzodiazepines (SBs) (elimination half-life ≤ 10 h). METHODS: we used base-line data and prospective fall follow-up from the Longitudinal Aging Study Amsterdam, a longitudinal cohort study including 1,509 community-dwelling older persons (Study 1) and from a separate fall prevention study with 564 older persons after a fall (Study 2). Time to the first fall after inclusion and number of falls in the first year after inclusion were the primary endpoints. RESULTS: both in Study 1 and Study 2 the use of SBs was associated with time to the first fall, hazard ratio (HR) 1.62 (95% CI: 1.03-2.56) and HR 1.64 (95% CI: 1.19-2.26),respectively. LBs were not significantly associated with time to first fall, HR 1.40 (0.85-2.31) and HR 1.08 (0.72-1.62). In both studies, the use of SBs was also associated with number of falls, odds ratio (OR) 1.28 (95% CI: 1.01-1.61) and OR 1.37 (95% CI: 1.10-1.70). LBs were not significantly associated with number of falls, OR 1.23 (0.96-1.57) and 1.10 (0.82-1.48). CONCLUSIONS: the use of SBs is not associated with a lower fall risk compared with LBs. The use of both SBs and LBs by old persons should be strongly discouraged.
Authors: Maartje H de Groot; Jos P C M van Campen; Marije A Moek; Linda R Tulner; Jos H Beijnen; Claudine J C Lamoth Journal: Drugs Aging Date: 2013-12 Impact factor: 3.923
Authors: Peter J H Scott; Xia Shao; Timothy J Desmond; Brian G Hockley; Phillip Sherman; Carole A Quesada; Kirk A Frey; Robert A Koeppe; Michael R Kilbourn; Nicolaas I Bohnen Journal: ACS Med Chem Lett Date: 2016-06-01 Impact factor: 4.345
Authors: Gretchen A Brenes; Suzanne C Danhauer; Mary F Lyles; Patricia E Hogan; Michael E Miller Journal: JAMA Psychiatry Date: 2015-10 Impact factor: 21.596
Authors: Lynna Chen; J Simon Bell; Renuka Visvanathan; Sarah N Hilmer; Tina Emery; Leonie Robson; Jessica M Hughes; Edwin C K Tan Journal: BMC Geriatr Date: 2016-11-26 Impact factor: 3.921
Authors: Rebecca Robbins; Ralph J DiClemente; Andrea B Troxel; Girardin Jean-Louis; Mark Butler; David M Rapoport; Charles A Czeisler Journal: Sleep Med Date: 2020-11-11 Impact factor: 3.492